Resources

Artemisinin-based combination therapy (ACT) is the primary malaria treatment in most malaria-endemic countries. To better understand the current ACT market and supply chain, PATH developed a market landscape with useful market information for stakeholders that purchase, procure, or use ACTs.The content of this landscape focuses on the current state of the ACT market—including supply, demand, market shares and prices, and active pharmaceutical ingredient and artemisinin suppliers.PATH hopes this landscape will be a valuable resource for partners, and we welcome any feedback or suggestions on the document.

A robust malaria surveillance system is the backbone of malaria control and elimination. Data visualization, analysis and use are critical to better understanding the data produced by malaria surveillance systems, assessing and communicating their implications for national malaria programs, and leveraging data and learnings to inform decision-making on implementation of malaria interventions.PATH's Malaria Control and Elimination Partnership in Africa (MACEPA) works with national malaria programs and district health teams to generate high-quality, actionable data products through functional surveillance systems, and increase data use for timely decision making. In collaboration with the Ministry of Health (MoH), PATH MACEPA in partnership with Bluesquare developed and facilitated the development and rollout of a national malaria intelligence platform to guide and inform malaria decision making in the Democratic Republic of the Congo (DRC).An overview of the process, challenges faced, lessons learned, and recommendations are documented and described in this technical brief.

In September 2024, the Kenya Ministry of Health published and disseminated an assessment report and technical brief exploring primary health care (PHC) implementation across Kisumu, Nakuru, Vihiga, Makueni, Garissa, Mombasa, and Nyeri counties. The analysis highlights Kenya's significant progress in establishing Primary Health Care Networks (PCNs) to improve access to essential services and emphasizes the important role PHC plays in achieving universal health coverage. PATH has been supporting the Ministry in the rollout of PCNs at the county level and was a critical partner in the analysis presented in the report.

Despite the ubiquity of aluminum adjuvants, they often present development, manufacturing, and quality challenges to manufacturers. As more and more manufacturers work toward World Health Organization prequalification, insights from a manufacturing, quality, analytical, and characterization perspective would be of high value. This PATH-organized webinar features speakers who are experts in the field, and covers:Chemistry and immunobiology of aluminum adjuvantsGood manufacturing practices for producing aluminum-based vaccine adjuvantsApproaches for modulating immune response qualityAdvancements in alum+ adjuvantsLessons learned with aluminum adjuvantsSpeakers include:Lakshmi Khandke, Sr. Program Advisor, Vaccines, CMC, Center for Vaccine Innovation and Access, PATHHarm HogenEsch, Professor of Immunology, Purdue UniversityLaurent Duroux, Lead Scientist, R&D, Vaccine Adjuvant Systems, CRODA PharmaRajesh Gupta, Principal Consultant, Biologics Quality & Regulatory Consultants LLCRobert Sitrin, Senior Scientist, Center for Vaccine Innovation and Access, PATHChristopher Fox, Senior Vice President of Formulations, Access to Advanced Health InstituteDerek O'Hagan, Senior Advisor, Vaccines R&D, GSK

As one of the earliest and largest investors in Gavi, the Vaccine Alliance, the United States government (USG) is a critical partner in Gavi's mission to increase access to lifesaving vaccines. PATH is working closely with our partners to advocate for increased investment from the USG, ahead of Gavi's next replenishment cycle for 2026-2030. We designed this community factsheet on Gavi's impact for use by advocates to support their engagements with Congress.